Biopharma 2021: The resilience rethink

2:00 PM - 2:45 PM (EDT), Thursday, June 17, 2021
Search General Info
Search Education
Search Partnering Companies

In an age of crisis, can the biopharma industry withstand global shocks?
2020 revealed uncomfortable truths about a sector that has become a globalized system of production, trade and distribution. At no point in the modern era have the health and resilience of the biopharma industry been more crucial. 

To assess the strength of the global industry and its capabilities, Cytiva has created the Global Biopharma Resilience Index. The index scores and ranks 20 countries on five factors — supply chain resilience, access to talent, strength of the R&D ecosystem, quality and agility of manufacturing processes, and effectiveness of government policy in supporting the industry. The overall index score for each country acts as a proxy for the strength of its biopharma industry.

This panel will discuss the joint report from Cytiva and The Financial Times on the new Resilience Index and the state of biopharma amid its biggest challenge yet.